{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:40:12Z","timestamp":1756183212831,"version":"3.44.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Complement opsonin C3b is at the center of the complement cascade. All complement initiation pathways converge when convertases activate C3, converting it into the anaphylatoxin C3a and the opsonin C3b, which can attach to surfaces via its freshly exposed thioester moiety. C3b has several important functions and remains a focus of basic and translational research. C3b and its proteolytically processed derivatives iC3b and C3dg are important opsonins for different complement receptors on various immune cells. C3b is the initiation nucleus for the formation of the alternative pathway C3 convertase and C3b clusters act as gatekeepers for the activation of C5, which initiates the terminal pathway. High densities of surface-deposited C3b alter the substrate specificity of complement convertases from C3 to C5 activation. It remains unknown how C3b achieves the \u201cC5 priming\u201d necessary for this process. Further exploration of the functions of C3b is laborious, as it generally requires the purification of C3 from plasma\/serum, subsequent conversion to C3b, and further purification. Therefore, we developed a rapid (three days) and efficient method that purifies C3b directly from blood sources, requiring fewer steps and reagents than previously published protocols. This method utilizes the newly exposed sulfhydryl group, which becomes accessible by converting C3 to C3b. The C3b purified by this method exhibits high purity and very high activity, as demonstrated by affinity measurements for several known C3b ligands, the formation and dissociation of the alternative pathway convertase, and the capacity to be regulated by FI.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1639735","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:08Z","timestamp":1756181588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel and rapid method to purify the human complement opsonin C3b from human plasma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jannik","family":"Sichau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2350816","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: Are we there yet, or just getting started","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-616300","article-title":"Dissecting complement blockade for clinic use","volume":"125","author":"Risitano","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25016","article-title":"Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria","volume":"93","author":"Risitano","year":"2018","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01639","article-title":"Different levels of incomplete terminal pathway inhibition by eculizumab and the clinical response of PNH patients","volume":"10","author":"Harder","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/imr.13164","article-title":"Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system","volume":"313","author":"Schmidt","year":"2023","journal-title":"Immunol Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough hemolysis in PNH with proximal or terminal complement inhibition","volume":"387","author":"Notaro","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27242","article-title":"Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Griffin","year":"2024","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011691","article-title":"Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH","volume":"8","author":"Griffin","year":"2024","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012672","article-title":"Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria","volume":"8","author":"Peffault de Latour","year":"2024","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault De Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"key":"B14","first-page":"29","article-title":"A new function of the activated third component of complement: binding to C5, an essential step for C5 activation","volume":"34","author":"Vogt","year":"1978","journal-title":"Immunology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12915-015-0203-8","article-title":"Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes","volume":"13","author":"Berends","year":"2015","journal-title":"BMC Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5","volume":"23","author":"Jore","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.122.2.277","article-title":"Isolation of beta IF-globulin from human serum and its characterization as the fifth component of complement","volume":"122","author":"Nilsson","year":"1965","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1016\/S0021-9258(19)69557-8","article-title":"Large scale isolation of functionally active components of the human complement system","volume":"256","author":"Hammer","year":"1981","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1042\/bj2050575","article-title":"A general method for affinity purification of complement component C3b using factor H-sepharose","volume":"205","author":"Scott","year":"1982","journal-title":"Biochem J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13.3.1","DOI":"10.1002\/0471142735.im1303s14","article-title":"Isolation and purification of C3 from human plasma","author":"O\u2019Rear","year":"1994","journal-title":"Curr Protoc Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1385\/1-59259-056-X:15","article-title":"Purification of complement components, regulators, and receptors by classical methods","volume":"150","author":"van den Berg","year":"2000","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature04005","article-title":"Structures of complement component C3 provide insights into the function and evolution of immunity","volume":"437","author":"Janssen","year":"2005","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature05172","article-title":"Structure of C3b reveals conformational changes that underlie complement activity","volume":"444","author":"Janssen","year":"2006","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.152.6.1625","article-title":"Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin","volume":"152","author":"Lambris","year":"1980","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e34820","DOI":"10.1371\/journal.pone.0034820","article-title":"Lack of evidence from studies of soluble protein fragments that Knops blood group polymorphisms in complement receptor-type 1 are driven by malaria","volume":"7","author":"Tetteh-Quarcoo","year":"2012","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.615748","article-title":"Deregulation of factor H by factor H-related protein 1 depends on sialylation of host surfaces","volume":"12","author":"Dopler","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2010.12.002","article-title":"Production of biologically active complement factor H in therapeutically useful quantities","volume":"76","author":"Schmidt","year":"2011","journal-title":"Protein Expr Purif"},{"key":"B29","article-title":"Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway","volume":"160","author":"Sahu","year":"1998","journal-title":"J Immunol Baltim Md"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.158.2.334","article-title":"Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin","volume":"158","author":"Ross","year":"1983","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.129.5.2051","article-title":"Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity","volume":"129","author":"Ross","year":"1982","journal-title":"J Immunol Baltim Md"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1385\/1-59259-249-X:105","article-title":"Functional analysis of the \u03b22 integrins","volume-title":"Integrin Protocols","author":"Li","year":"1999"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.72.8.3029","article-title":"A rapid and specific method for isolation of thiol-containing peptides from large proteins by thiol-disulfide exchange on a solid support","volume":"72","author":"Egorov","year":"1975","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3427","article-title":"Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses","volume":"24","author":"Xue","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature05263","article-title":"Structure of C3b in complex with CRIg gives insights into regulation of complement activation","volume":"444","author":"Wiesmann","year":"2006","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201593673","article-title":"Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode","volume":"35","author":"Forneris","year":"2016","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(80)90260-4","article-title":"An improved three-step method for the purification of the third component of human complement","volume":"35","author":"Davrinche","year":"1980","journal-title":"J Immunol Methods"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1006\/prep.1994.1027","article-title":"The fractionation of human plasma proteins. II. The purification of human complement proteins C3, C3u, and C5 by application of affinity chromatography","volume":"5","author":"DiScipio","year":"1994","journal-title":"Protein Expr Purif"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1042\/bj1910173","article-title":"Purification of the human complement control protein C3b inactivator","volume":"191","author":"Crossley","year":"1980","journal-title":"Biochem J"},{"key":"B41","article-title":"Inhibition of factor I by diisopropylfluorophosphate. Evidence of conformational changes in factor I induced by C3b and additional studies on the specificity of factor I","volume":"144","author":"Ekdahl","year":"1990","journal-title":"J Immunol Baltim Md"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M709587200","article-title":"Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations","volume":"283","author":"Hocking","year":"2008","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341305","article-title":"Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes","volume":"118","author":"Tham","year":"2011","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200357","article-title":"Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3","volume":"189","author":"Kopp","year":"2012","journal-title":"J Immunol Baltim Md"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12837","article-title":"Interplay between fibrinolysis and complement: plasmin cleavage of iC3b modulates immune responses","volume":"13","author":"Foley","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02427-14","article-title":"A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b","volume":"89","author":"Johnson","year":"2015","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e12766","DOI":"10.1002\/rth2.12766","article-title":"Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners","volume":"6","author":"Li","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.607641","article-title":"The sez6 family inhibits complement by facilitating factor I cleavage of C3b and accelerating the decay of C3 convertases","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1086\/344515","article-title":"Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome","volume":"71","author":"S\u00e1nchez-Corral","year":"2002","journal-title":"Am J Hum Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:09Z","timestamp":1756181589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2025.1639735"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1639735","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1639735"}}